Skip to main content

Key Takeaways:

  1. Decentralized Randomized Trials: Enable genomic research and clinical studies to be conducted remotely, increasing access and diversity of participants.
  2. Digital Technologies: Leverage tools like telemedicine, mobile apps, and wearable devices to collect data from participants in their homes.
  3. Advantages: Reduced costs, increased enrollment, better representation, and real-world evidence generation.
  4. Challenges: Addressing data privacy/security concerns, protocol adherence, and regulatory acceptance.
  5. Potential Impact: To accelerate genomic medicine through more efficient evidence generation from diverse populations.

The Decentralized Trial Model

Decentralized randomized trials enable genomic research and clinical studies to be conducted remotely with participants in their homes and communities. These trials utilize a suite of tools, including telemedicine, mobile apps, wearable biosensors, and direct-to-participant drug shipments. Genomic data, such as DNA samples for sequencing, are collected via at-home testing kits.

Benefits of Decentralization

This digital approach offers several potential advantages. It provides increased access for populations that may live far from academic medical centers or have mobility limitations. By broadening the geographic reach, decentralized trials help increase diversity and better represent the genetic variation across different racial, ethnic, and socioeconomic groups. Additionally, conducting research in real-world settings generates more naturalistic data on how investigational products perform in participants’ daily lives.

Operational Efficiencies

The decentralized model offers operational efficiencies that can streamline logistics and reduce infrastructure costs associated with traditional brick-and-mortar trial sites. This efficiency can accelerate study timelines and improve enrollment and retention rates by making participation more convenient for volunteers.

Challenges and Barriers

While promising, the adoption of decentralized trials faces challenges, particularly around data privacy and security. Robust protocols must protect participant confidentiality, and ensuring adherence can be more difficult remotely compared to in-clinic visits. Regulators will require thorough evidence to prove that decentralized approaches reliably achieve research objectives.

Current Applications in Genomics

Despite these hurdles, many initiatives are utilizing decentralized trials across disease areas. The NIH’s All of Us Research Program and genomic screening studies like CIRCLE employ digital technologies and at-home sample collection. Pharmaceutical companies have launched decentralized trials for genomically-targeted cancer therapies.

The Future of Decentralized Genomic Research

As supportive evidence grows, the decentralized paradigm is poised to transform genomic research. By capitalizing on digital health tools, this model can accelerate precision medicine by enabling more efficient generation of real-world genomic evidence from diverse populations worldwide. Prioritizing the overcoming of barriers is crucial to achieving this goal.

 

Sources:

  1. Khozin, S., & Coravos, A. (2019). Decentralized trials in the age of real-world evidence and inclusiveness in clinical investigations. Clinical Pharmacology & Therapeutics, 106(1), 25-27. [Journal article discussing benefits and challenges of decentralized trials]
  2. Fogel, D. B. (2017). Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemporary Clinical Trials Communications, 11, 156-164. [Review analyzing factors impacting clinical trial success rates]
  3. Walter, J., Fried, J., & Haeussler, J. (2020). Decentralized versus Traditional Clinical Trials. Digitrx (white paper). [White paper from digital clinical trials company Digitrx comparing models]
  4. Sommer, C., Zuckerman, B., Moore, K., & Applicators, P. T. (2020). Decentralized clinical trials: a data-driven introduction. Applied Clinical Trials, 29, 25-27. [Article providing data-driven overview of decentralized trials]
  5. Nabizadeh, S., Phillips, S., Grennan, D., & Walton, S. M. (2022). Decentralized clinical trials: benefits and challenges. Therapeutic Innovation & Regulatory Science, 56(4), 537-548. [Recent journal article analyzing benefits and challenges]